CARLSBAD, CA--(BUSINESS WIRE)--Gordon Robert Alton, PhD joins BriOri BioTech as COO. BriOri is an emerging pre-clinical stage biotech company focused on developing a pipeline of opiate-free topical pain medications including its March 1, 2022, 20-year patent, for “Topical Compositions Containing Rofecoxib® (Vioxx®) and Methods of Making and Using the Same.” The topical reformulation of the oral medication Vioxx®, a COX-2 specific NSAID, aims to alleviate osteoarthritis related pain of the knee and joints which affects over 32 million people in the U.S. alone without opioids or adverse side effects like GI bleeds, strokes, and cardiovascular events due to the systemic exposure associated with oral NSAID dosing.
CARLSBAD, Calif.--(BUSINESS WIRE)--BriOri BioTech, an emerging pre-clinical stage biotech company focused on developing a pipeline of opiate-free topical pain medications, announces its patent for “Topical Compositions Containing Rofecoxib (Vioxx) and Methods of Making and Using the Same” was issued on March 1, 2022. This patent covers a reformulation of Vioxx, a COX-2 specific NSAID, from an oral to topical formulation with the intention of alleviating osteoarthritis related pain of the knee and joint pain, and reducing the need for opioids in certain patient populations. With the global market for topical pain relief treatments estimated to be $8.8 billion in 2019 and projected to grow to $12.2 billion by 2027, BriOri BioTech aims to bring a safer and more effective solution to the market to meet a large unmet need.